Search for Bristol-Myers Squibb Co and
    1. September 26, 2014

      Battling cancer: Focus turns to defence as best form of attack

      It has been described as the beginning of the end of cancer. A new wave of drugs that harnesses the body’s immune system to...

    2. September 26, 2014

      Drug development: Big pharma back in the game it made

      Big pharma is back. That, at least, is the impression created by a wave of new cancer drugs rapidly approaching market....

    Special Reports

    1. Combating Cancer

      A wave of drugs that harnesses the body’s immune system is fuelling optimism that scie...
    2. Combating Hepatitis C

      Treatment for the virus is in the midst of its biggest advance for at least a decade a...
    Search more Special Reports on this topic.

    1. August 4, 2014

      Bristol-Myers Squibb in venture to turn US research into drugs

      Allied Minds, a Boston-based science and technology development company, has joined forces with biopharmaceutical giant...

    2. July 31, 2014

      Drug pricing: Bitter pill

      When delegates turned up for a big healthcare conference at New York’s plush Waldorf Astoria hotel in February, they were...

    3. July 27, 2014

      Hepatitis C researchers battle to ‘nuke’ the competition

      Idenix has fewer than 100 employees and no products on the market. So what was it that persuaded Merck to pay $3.85bn – more...

    4. July 16, 2014

      Eli Lilly joins forces with UK biotech to develop cancer drugs

      Eli Lilly has entered the race to develop a new generation of oncology drugs, which harness the immune system to kill cancer...

    5. June 29, 2014

      Green chemistry: Pharmaceutical companies try to clean up their act

      Pharmaceutical companies tend to highlight their role in saving lives, but say little about the impact their manufacturing...

    6. June 10, 2014

      Hepatitis C: Gilead’s Odyssey

      The Hepatitis C virus is the kind of problem that drug companies are meant to solve. The World Health Organisation thinks as...

    7. May 30, 2014

      Hopes for cancer cures offer comfort for battered pharma

      It is the Holy Grail of medical science. Ever since Hippocrates, the Greek physician, first described the disease more than...

    8. FT Alphaville

      May 6, 2014

      About that AstraZeneca bid defence ...

      The nationalistic bluster around AstraPfizica remains blustery. Here, for example, is London Mayor Boris Johnson: It would...

    9. April 13, 2014

      Drug groups step up race for hepatitis C treatments

      Drugmakers are stepping up the race for multibillion-dollar hepatitis C treatments after trial data showed how the disease...

    10. April 1, 2014

      Bristol-Myers Squibb: side effects

      One of these things is not like the others, as Big Bird sings. Look at the mega-cap pharma and biotech stocks. In the near...

    11. January 27, 2014

      Hepatitis C: Treated – at a price

      Gemma Peppe lived with hepatitis C for two decades before she – and the teenage son she inadvertently infected at birth –...

    12. FT Alphaville

      December 19, 2013

      The (early) Lunch Wrap

      Good morning New York, FT ALPHAVILLE Izzy continues to expand her theory of money entanglement, a look at the relationship...

    13. December 19, 2013

      AstraZeneca in $4bn buyout of diabetes venture partner

      AstraZeneca is to buy out its joint venture with Bristol-Myers Squibb in a deal worth up to $4.3bn, as it seeks to...

    14. November 8, 2013

      Bristol-Myers Squibb could realise $6bn from diabetes franchise

      Bristol-Myers Squibb could generate up to $6bn from the sale of its diabetes franchise, according to an analyst’s projection...

    15. FT Alphaville

      October 24, 2013

      Does this stock need medicating?

      It’s Shire, of course, reacting to a warning of better than expected earnings. The stock was up 8.7 per cent at 2744p at...

    16. September 16, 2013

      S&P 500 breaks back above 1,700

      The S&P 500 broke back above the 1,700 level in intraday trading on Monday as US equities rallied and bond yields fell...

    17. August 25, 2013

      Amgen’s $10.5bn takeover of Onyx approved by both boards

      Amgen said on Sunday night that its takeover of Onyx, the US cancer drug developer, at $125 a share had been approved by...

    18. June 10, 2013

      Markets Insight: The Fed has turned markets upside down

      Stellar performance across most asset classes has been the norm until recently. Equity markets are up sizeably and, in some...

    19. June 3, 2013

      Carmakers help fuel US stocks

      Auto companies were in focus on the first trading day of June, as the S&P 500 recovered from morning losses to finish the...

    20. May 22, 2013

      US stocks step back from intraday highs

      An afternoon sell-off knocked US stocks back from intraday record highs as investors weighed the Federal Reserve’s...

    21. April 29, 2013

      US pharma: spot the difference

      The big US drug companies look eerily alike. Pfizer, Merck, Eli Lilly and AbbVie (formerly Abbott) are all expanding...

    22. beyondbrics

      April 17, 2013

      Big Pharma says Olá to Brazil

      By Pan Kwan Yuk and Thalita Carrico Brazil’s burgeoning middle class might have helped propel the country to the top of the...

    23. December 20, 2012

      Eli Lilly settles bribery charges

      Eli Lilly, the US pharmaceutical company, has agreed to pay $30m to settle charges that it engaged in a scheme to bribe...

    24. November 30, 2012

      Teva restructuring beckons

      Teva, the world’s largest generic drugs company, unveiled 2013 sales and earnings guidance below market expectations,...

    25. November 29, 2012

      Research: Scientists turn attention to prevention and cure

      “Getting to zero” – meaning no new infections or deaths from HIV – is the slogan for World Aids Day. Until recently such a...

    26. November 29, 2012

      Corporate: Sweetening the pill

      Any significant transaction has challenges – which may be related to regulation, competition or price. And while it is up to...

    27. October 15, 2012

      US equities boosted by retail data

      Citigroup shares gained as the US bank beat market expectations for the third quarter, despite reporting an 88 per cent fall...

    28. August 28, 2012

      AstraZeneca – a new big pill

      A newly arriving chief executive has many tasks: strategy, turnround, growth, redecorating the corner office. Pascal Soriot...

    29. July 15, 2012

      Diagnostics creating ‘niche buster’ drugs

      When US regulators this month authorised a genetic test that determines whether or not patients will benefit from a cancer...

    30. July 2, 2012

      Deal boosts AstraZeneca’s interim chief

      The $7bn planned acquisition of Amylin announced this weekend is an indicator of interest in the fast-growing diabetes...

    31. July 1, 2012

      BMS / Amylin

      Bad habits equal big opportunities. As the world’s population gets fatter, diabetes is on the rise. The World Health...

    32. July 1, 2012

      AstraZeneca eyes more deals after Amylin

      AstraZeneca has the cash and appetite for more new acquisitions, the acting head of the Anglo-Swedish pharmaceutical group...

    33. June 30, 2012

      BMS and AstraZeneca to acquire Amylin

      Bristol-Myers Squibb is to take control of Amylin, the US biotech, in a complex $7bn joint deal with AstraZeneca that will...

    34. June 26, 2012

      FDA accuses Amylin of withholding info

      A top US regulator has accused Amylin, the biotech company, of withholding important information on cardiac side effects of...

    35. June 5, 2012

      BMS / AstraZeneca: good twin, bad twin

      They could be twins. But they are not identical. The US’s Bristol-Myers Squibb and the UK’s AstraZeneca are both...

    36. May 31, 2012

      AstraZeneca prepares for upheaval

      The new chairman of AstraZeneca says his top priority is finding a permanent chief executive for the troubled Anglo-Swedish...

    37. May 22, 2012

      Global pharma: time to do drugs?

      When times are hard, do drugs. In the stock market, this advice is dogma. Shares of global pharma companies are...

    38. May 15, 2012

      AstraZeneca among suitors eyeing Amylin

      Amylin Pharmaceuticals, the US maker of diabetes-focused medicines, has attracted a string of potential suitors, including...

    Search for Bristol-Myers Squibb Co and